Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Tarsus Pharmaceuticals's cash was $449.69M at Jun 30, 2026. For fiscal 2025 it was $417.27M, up 42.0% from the year before. The highest annual figure on record is $417.27M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $417.27M | +42.0% |
| FY2024 | Dec 31, 2024 | $293.94M | +29.2% |
| FY2023 | Dec 31, 2023 | $227.44M | +4.8% |
| FY2022 | Dec 31, 2022 | $217.03M | +26.3% |
| FY2021 | Dec 31, 2021 | $171.82M | +2.2% |
| FY2020 | Dec 31, 2020 | $168.15M | +190.1% |
| FY2019 | Dec 31, 2019 | $57.97M | +2340.9% |
| FY2018 | Dec 31, 2018 | $2.38M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $449.69M | +17.2% |
| Q1 FY2026 | Mar 31, 2026 | $388.73M | -5.3% |
| Q4 FY2025 | Dec 31, 2025 | $417.27M | +42.0% |
| Q3 FY2025 | Sep 30, 2025 | $401.84M | +26.8% |
| Q2 FY2025 | Jun 30, 2025 | $383.71M | +18.6% |
| Q1 FY2025 | Mar 31, 2025 | $410.48M | +37.5% |
| Q4 FY2024 | Dec 31, 2024 | $293.94M | +29.2% |
| Q3 FY2024 | Sep 30, 2024 | $316.95M | +28.4% |
| Q2 FY2024 | Jun 30, 2024 | $323.58M | +81.6% |
| Q1 FY2024 | Mar 31, 2024 | $298.52M | +48.4% |
| Q4 FY2023 | Dec 31, 2023 | $227.44M | +4.8% |
| Q3 FY2023 | Sep 30, 2023 | $246.89M | +9.0% |
| Q2 FY2023 | Jun 30, 2023 | $178.23M | -27.4% |
| Q1 FY2023 | Mar 31, 2023 | $201.22M | +14.8% |
| Q4 FY2022 | Dec 31, 2022 | $217.03M | +26.3% |
| Q3 FY2022 | Sep 30, 2022 | $226.57M | +23.3% |
| Q2 FY2022 | Jun 30, 2022 | $245.36M | +38.8% |
| Q1 FY2022 | Mar 31, 2022 | $175.30M | +12.2% |
| Q4 FY2021 | Dec 31, 2021 | $171.82M | +2.2% |
| Q3 FY2021 | Sep 30, 2021 | $183.80M | +112.9% |
| Q2 FY2021 | Jun 30, 2021 | $176.74M | +232.6% |
| Q1 FY2021 | Mar 31, 2021 | $156.18M | +179.4% |
| Q4 FY2020 | Dec 31, 2020 | $168.15M | +190.1% |
| Q3 FY2020 | Sep 30, 2020 | $86.33M | +25516.9% |
| Q2 FY2020 | Jun 30, 2020 | $53.14M | +2137.3% |
| Q1 FY2020 | Mar 31, 2020 | $55.89M | – |
| Q4 FY2019 | Dec 31, 2019 | $57.97M | – |
| Q3 FY2019 | Sep 30, 2019 | $337.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $2.38M | – |
See a number that looks wrong?